~~<i id='B38F3F57E9'><strike id='B38F3F57E9'><tt id='B38F3F57E9'><pre id='B38F3F57E9'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：knowledge 2025-10-04 06:49:16 Page View：9726

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： STAT Virtual Event: ASCO Recap, Live!
Next article： What does generative AI mean for health care? We asked experts

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Neurocrine congenital adrenal hyperplasia trial succeeds

AdobeSANDIEGO—NeurocrineBiosciencesannouncedonTuesdaythatanexperimentaldrugforcongenitaladrenalhyper

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

FDA weighs limits of animal data in assessing artificial wombs

APStockTheFoodandDrugAdministration’sadvisorypanelofpediatricexpertsmetonTuesdaytodiscussadvancesina